Pre-illness Isoflavone Consumption and Disease Risk of Ulcerative Colitis: a Multicenter Case-control Study in Japan
Overview
Authors
Affiliations
Introduction: Previous studies have suggested that estrogens play a role in the development of ulcerative colitis (UC). Because isoflavones have a similar structure to 17β-estradiol, dietary consumption of isoflavones may have similar influences on the development of UC. We examined the association between pre-illness isoflavone consumption and the risk of UC.
Materials And Methods: We conducted a hospital-based case control study, and compared the dietary habits of 126 newly diagnosed UC cases with those of 170 age- and gender-matched hospital controls. Information on dietary factors was collected using a self-administered diet history questionnaire. To consider potential changes in dietary habits due to disease symptoms, the habits were assessed separately during the previous 1 month and at 1 year before the recruitment.
Results: In the assessment of dietary habits during the previous 1 month, the highest tertile of isoflavone consumption revealed an increased odds ratio (OR) for UC (OR = 2.79; 95% confidence interval (CI), 1.39-5.59; Trend P = 0.004). A significant association was also observed for the dietary assessment at 1 year before, when most UC cases had not yet experienced their first disease symptoms (OR = 2.06; 95% CI, 1.05-4.04; Trend P = 0.04). Associations were more pronounced in females (OR in highest tertile of isoflavone consumption at 1 year before = 4.76; 95% CI, 1.30-17.5; Trend P = 0.02) but were obscured in males (corresponding OR = 1.21; 95% CI, 0.49-3.01; Trend P = 0.63).
Conclusions: Dietary isoflavone consumption may be associated with an increased risk of UC, particularly in females. Prospective cohort studies are warranted to confirm these findings.
Boaru D, Fraile-Martinez O, De Leon-Oliva D, Garcia-Montero C, De Castro-Martinez P, Miranda-Gonzalez A Int J Biol Sci. 2024; 20(14):5608-5672.
PMID: 39494333 PMC: 11528451. DOI: 10.7150/ijbs.98107.
Kondo K, Ono Y, Ohfuji S, Watanabe K, Yamagami H, Watanabe M JGH Open. 2023; 7(1):61-67.
PMID: 36660047 PMC: 9840195. DOI: 10.1002/jgh3.12857.
Nishida Y, Nakamura H, Sasaki S, Shirahata T, Sato H, Yogi S BMJ Open Respir Res. 2021; 8(1).
PMID: 34362765 PMC: 8351478. DOI: 10.1136/bmjresp-2020-000807.
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.
Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T J Gastroenterol. 2021; 56(6):489-526.
PMID: 33885977 PMC: 8137635. DOI: 10.1007/s00535-021-01784-1.
(Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review.
Hagan M, Hayee B, Rodriguez-Mateos A Molecules. 2021; 26(7).
PMID: 33805938 PMC: 8036772. DOI: 10.3390/molecules26071843.